Dyne Therapeutics Inc expected to post a loss of 92 cents a share - Earnings Preview

Dyne Therapeutics

27/02/2024 15:43

* Dyne Therapeutics Inc  DYN.OQ   DYN.O  is expected to show
no
change in quarterly revenue when it reports  results on February
29 (estimated) for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Dyne Therapeutics Inc is
for a
loss of 92 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 9 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Dyne
Therapeutics
Inc is $35.50​, above​ its last closing price of $24.04. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.82       -0.83      -0.99     Missed  -18.9
 Jun. 30 2023  -0.79       -0.81      -1.08     Missed  -33.7
 Mar. 31 2023  -0.76       -0.77      -0.78     Missed  -1.5​
 Dec. 31 2022  -0.80       -0.84      -0.74     Beat    12.4
 ​​Sep.        -0.91       -0.92      -0.80     Beat    13.2
 30 2022                                                
 Jun. 30 2022  -0.76       -0.77      -1.01     Missed  -30.3​
 Mar. 31 2022  -0.88       -0.88      -0.69     Beat    21.8
 Dec. 31 2021  -0.99       -0.99      -1.00     Missed  -1
 This summary was machine generated February 27 at 15:42 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)